Our Pipeline

Ianalumab is an antibody that targets B-cell activating factor receptor (BAFF-R), designed to block BAFF-R-mediated signaling and to deplete B-cells through antibody-dependent cellular cytotoxicity. It is being investigated in multiple Phase 3 studies, including for Sjögren’s disease, lupus nephritis, systemic lupus erythematosus, immune thrombocytopenia (first-line and second-line) and warm autoimmune hemolytic anemia, and a Phase 2/3 study for autoimmune hepatitis. 

Abelacimab is an antibody that selectively binds and blocks the activity of Factor XI and its active form Factor XIa, to protect against thromboembolic events. It is being investigated in a Phase 3 study in patients with atrial fibrillation (AF), and in two ongoing complementary Phase 3 studies in patients with cancer-associated thrombosis (CAT). A Phase 2 study in AF was stopped early due to an overwhelming benefit (reduction in bleeding). Abelacimab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in both the AF and CAT indications.

Setrusumab is an antibody that inhibits sclerostin, a negative regulator of bone formation. It is being investigated in the Phase 3 portion of a pivotal Phase 2/3 clinical study and in a Phase 3 study, both for the treatment of osteogenesis imperfecta (OI). The studies are supported by positive Phase 2 data demonstrating that setrusumab significantly reduced fracture rates in patients with OI. Setrusumab has been granted Rare Pediatric Disease Designation by the FDA.

Bimagrumab is an antibody that binds activin type II A and B receptors to block activin and myostatin signaling, which can cause wasting in muscles and storage of fat in adipose tissue. It is currently being investigated in a Phase 2b study as a novel treatment for overweight and obesity, as both a monotherapy and in combination with semaglutide. 

Felzartamab is an antibody that targets CD38, a protein broadly expressed on malignant myeloma cells and antibody-producing plasmablasts and plasma cells. It is being investigated by HI-Bio in two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy and immunoglobulin A nephropathy. These studies are supported by positive Phase 2 data and a recent FDA Breakthrough Therapy designation in primary membranous nephropathy. Felzartamab is also being investigated by TJ Biopharma (früher I-Mab Biopharma) in relapsed/refractory multiple myeloma.

MOR210/TJ210/HIB210 is an antibody that targets C5aR1, the receptor of the complement factor C5a, a novel therapeutic target with potential in the fields of autoimmune diseases and immuno-oncology. It is being investigated by TJ Biopharma (früher I-Mab Biopharma) for the treatment of advanced solid tumors and by HI-Bio in a Phase 1 study in healthy volunteers.